GLP1R and idiopathic cardiomyopathy: Although the usage of ACEi, ARB, and β-blocker could not reduce the risks of idiopathic cardiomyopathy, the patients taking metformin, meglitinides, TZD, DPP4i, SGLT-2i, and GLP-1 had substantially lower risks of suffering from idiopathic cardiomyopathy.